Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59–1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.
Plain language summary
What is this article about?
This article looked at the outcomes of patients with triple-class exposed relapsed/refractory multiple myeloma (MM), who were treated with the bispecific antibody teclistamab in the MajesTEC-1 trial and analyzed how they compared with outcomes of similar patients from the nationwide deidentified electronic health record derived Flatiron Health multiple myeloma cohort database (real-world physician’s choice cohort).
What were the results?
Patients treated with teclistamab in the MajesTEC-1 study had statistically better progression-free survival (hazard ratio [HR]: 0.43 [95% CI: 0.33–0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p < 0.0001) and numerically better overall survival (HR: 0.82 [0.59–1.14]; p = 0.233), compared with patients in the real-world physician’s choice cohort. Any imbalances in baseline characteristics of prognostic significance in the two groups of patients were adjusted to ensure statistical comparability.
What do the results of the study mean?
These findings highlight the clinical benefit of teclistamab relative to other therapies for relapsed/refractory MM, which is particularly relevant for physicians caring for patients who are triple-class exposed and have limited remaining treatment options.
Formats available
You can view the full content in the following formats:
Supplementary Material
File (supplementary materials.docx)
- Download
- 45.49 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Stalker ME, Mark TM. Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr. Oncol. 29, 4464–4477 (2022).
2.
American Cancer Society. Cancer Facts and Figures 2020. American Cancer Society, GA, USA (2020). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
3.
Kyle RA, Rajkumar SV. Multiple myeloma. Blood 111, 2962–2972 (2008).
4.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 5.2022. www.nccn.org/guidelines/guidelines-detail?category=1&id=1445
•• Guidelines for the treatment of multiple myeloma are provided.
5.
Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study. Clin. Ther. 43, 1983–1996.e3 (2021).
6.
Mateos MV, Weisel K, De Stefano V et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 36, 1371–1376 (2022).
7.
Lonial S, Lee HC, Badros A et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase II study. Lancet Oncol. 21, 207–221 (2020).
8.
Chari A, Vogl DT, Gavriatopoulou M et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727–738 (2019).
9.
Munshi NC, Anderson LD Jr, Shah N et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
10.
Martin T, Usmani SZ, Berdeja JG et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41(6), 1265–1274 (2022).
11.
Janssen Biologics B.V. TECVAYLI. Summary of Product Characteristics. European Medicines Agency, 1–49. www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf
12.
Janssen Biotech, Inc. TECVAYLI (teclistamab-cqyv). Janssen Biotech, Inc, PA, USA (2022).
13.
Moreau P, Garfall AL, van de Donk NWCJ et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).
•• The results of Phase I/II of the MajesTEC-1 trial are presented.
14.
Costa LJ, Hari P, Berdeja JG et al. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Curr. Med. Res. Opin. 38(10), 1759–1767 (2022).
15.
Martin T, Krishnan A, Yong K et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem 3, 97–108 (2021).
• Flatiron versus cilta-cel indirect comparison.
16.
Martin T, Usmani SZ, Schecter JM et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr. Med. Res. Opin. 37, 1779–1788 (2021).
17.
Shah N, Mojebi A, Ayers D et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J. Comp. Eff. Res. 11(10), 737–749 (2022).
18.
Weisel K, Krishnan A, Schecter JM et al. Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 22, 690–701 (2022).
19.
Weisel K, Martin T, Krishnan A et al. Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. Clin. Drug Investig. 42, 29–41 (2022).
20.
Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv (2020). www.medrxiv.org/content/10.1101/2020.03.16.20037143v2
21.
Birnbaum B, Nussbaum N, Seidl-Rathkopf K et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv (2020). https://arxiv.org/abs/2001.09765
22.
Joseph NS, Kaufman JL, Dhodapkar MV et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J. Clin. Oncol. 38, 1928–1937 (2020).
23.
Gandhi UH, Cornell RF, Lakshman A et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266–2275 (2019).
• Real-world study of relapsed/refractory multiple myeloma (RRMM).
24.
Usmani S, Ahmadi T, Ng Y et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist 21, 1355–1361 (2016).
• Real-world study of RRMM.
25.
Kumar SK, Dimopoulos MA, Kastritis E et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31, 2443–2448 (2017).
• Real-world study of RRMM.
Information & Authors
Information
Published In
Copyright
© 2023 Janssen Global Services, LLC. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 28 October 2022
Accepted: 31 March 2023
Published online: 28 April 2023
Keywords:
Topics
Authors
Funding Information
Janssen Global Services
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2022-0186
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Shaji Kumar, Katja C. Weisel, Paul Spin, Nicolle Bonar, Muhaimen Siddiqui, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael E. D. West, Christian Hampp, Jeannette Green, James Harnett, Olivier Humblet, Alexander Breskin, Wenzhen Ge, Jessica J. Jalbert, Rachel E. Sobel, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Sundar Jagannath, Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States, Blood Cancer Journal, 10.1038/s41408-026-01470-6, (2026).
- Binod Dhakal, Moshe Y. Levy, Gilbert Ko, Jinghua He, Nina Kim, Wenze Tang, Tonya Le Blanc, Jessica Fowler, Sarah Lucht, Madison Brown, Emily Bland, Camryn Craig, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Niodita Gupta-Werner, Shuchita Kaila, Peter Voorhees, Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study, Oncology and Therapy, 10.1007/s40487-026-00429-8, (2026).
- Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David S. Siegel, Jorge Monge, Juan Du, Javier de la Rubia, Pedro Asensi Cantó, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Blade, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle Bonar, Paul Spin, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Michael E. D. West, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Brian G. M. Durie, Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma, Blood Cancer Journal, 10.1038/s41408-026-01466-2, 16, 1, (2026).
- Finn Segers, Michel Delforge, Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?, Targeted Oncology, 10.1007/s11523-025-01189-7, 21, 1, (63-86), (2026).
- Shaji Kumar, Xavier Leleu, Katja C. Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp, Wenzhen Ge, Qiufei Ma, Sundar Jagannath, Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review, Clinical Lymphoma Myeloma and Leukemia, 10.1016/j.clml.2025.03.013, 25, 10, (730-738.e11), (2025).
- Jun Ho Yi, Dok Hyun Yoon, Kihyun Kim, Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time, Seminars in Hematology, 10.1053/j.seminhematol.2025.11.003, 62, 4, (305-318), (2025).
- Wenze Li, Defeng Zhao, Yu Jiao, Weilin Dong, Ziyi Wang, Xiaojing Yan, Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis, Frontiers in Immunology, 10.3389/fimmu.2025.1565407, 16, (2025).
- Simone Karp, Karolin Trautmann-Grill, Paul Warncke, Dominik Zolnowski, Christoph Röllig, Marcel Pannach, Jessica Zinn, Frank Kroschinsky, Anke Morgner, Malte von Bonin, Annette Hänel, Regina Herbst, Stephan Fricke, Martin Bornhäuser, Mathias Hänel, Raphael Teipel, Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?, Annals of Hematology, 10.1007/s00277-025-06262-9, 104, 3, (1735-1745), (2025).
- Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Steve Peterson, Luciano J. Costa, Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 10.1016/j.clml.2024.08.003, 25, 2, (124-134.e5), (2025).
- Fabian Ullrich, Paul J Bröckelmann, Amin T Turki, Abdullah M Khan, Elena-Diana Chiru, Marcus Vetter, Bastian von Tresckow, Rainer Wirth, Raul Cordoba, Valentín Ortiz-Maldonado, Tamas Fülöp, Nina Rosa Neuendorff, Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma, Journal for ImmunoTherapy of Cancer, 10.1136/jitc-2024-009462, 12, 12, (e009462), (2024).
- See more